News & Updates
Filter by Specialty:
Final PROpel data confirm OS advantage with abiraterone plus olaparib
The combination of olaparib plus abiraterone in the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC) appears to show a consistent trend toward overall survival (OS) benefit, according to the results of the final prespecified analysis of the phase III PROpel study presented at ASCO GU 2023.
Final PROpel data confirm OS advantage with abiraterone plus olaparib
01 Mar 2023Use of biomarkers, biologics ups success rate of clinical trials in gastric cancer
Success rates of clinical trials in gastric cancer tend to improve with the use of implementing biomarkers, receptor-targeted therapies, and biologics in clinical development, suggests a recent study.
Use of biomarkers, biologics ups success rate of clinical trials in gastric cancer
01 Mar 2023Statin therapy reduces major vascular events after stroke
Treatment with statin results in a decrease in major vascular events following acute ischaemic stroke, even in patients with low or well-controlled low-density lipoprotein cholesterol (LDL-C), as shown in a study presented at ISC 2023.
Statin therapy reduces major vascular events after stroke
01 Mar 2023DOACs, VKAs show similar efficacy, safety for VTE in octogenarians
In an international multi-database cohort study, direct oral anticoagulants (DOACs) demonstrated comparable efficacy and safety with vitamin K antagonists (VKAs) for octogenarians with venous thromboembolism (VTE).
DOACs, VKAs show similar efficacy, safety for VTE in octogenarians
01 Mar 2023Mental illness in homelessness: What are the determinants?
Female gender, chronic disease and food insecurity are risk factors for major depressive disorder (MDD) and generalized anxiety disorder (GAD) in homeless individuals, while respect from others is a protective factor for both disorders, a territory-wide study has shown.